Publication date: May 21, 2025
Tixagevimab-cilgavimab was available for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) prevention from December 2021 to January 2023, with dosing changes to reflect circulating variants. In a retrospective analysis of 597 immunocompromised individuals, incidence of SARS-CoV-2 infection was compared between those who did and did not receive tixagevimab-cilgavimab. A proportional hazards regression model with a time-dependent regressor for tixagevimab-cilgavimab dose was applied to assess cumulative doses. Secondary analyses were performed in hematopoietic stem cell transplant (HSCT) and chimeric antigen receptor (CAR)-T cell therapy recipients. There was no difference in SARS-CoV-2 infections between tixagevimab-cilgavimab recipients and controls (p = 0. 27). There was a trend towards protection with increasing dose from 150 (HR 0. 83, CI 0. 50-1. 38) to 600 mg (HR 0. 48, CI 0. 06-3. 63) when truncating data on November 1st, 2022, which was also seen in HSCT or CAR-T cell therapy recipients, 150 mg (HR 0. 71, CI 0. 31-1. 65) to 600 mg (HR 0. 26, CI 0. 01-7. 47). This was most evident in immunocompromised individuals when variants neutralized by tixagevimab-cilgavimab in vitro were circulating; effectiveness 74%. Supports a proof of concept for monoclonal antibodies in immunocompromised individuals as a prevention strategy against novel viruses.
Open Access PDF
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | SARS-CoV-2 infection |
| pathway | REACTOME | SARS-CoV-2 Infection |
| disease | IDO | cell |
| disease | MESH | infections |
| disease | MESH | morbidity |
| disease | IDO | infection |
| disease | MESH | Infectious Diseases |
| disease | MESH | Allergy |
| drug | DRUGBANK | Coenzyme M |
| disease | MESH | death |
| disease | MESH | Emergency |
| disease | MESH | Immunocompromised Host |